NASDAQ:MGX Metagenomi Q1 2026 Earnings Report $1.32 +0.01 (+0.38%) As of 10:00 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Metagenomi EPS ResultsActual EPS-$0.61Consensus EPS -$0.60Beat/MissMissed by -$0.01One Year Ago EPSN/AMetagenomi Revenue ResultsActual Revenue$1.25 millionExpected Revenue$5.90 millionBeat/MissMissed by -$4.66 millionYoY Revenue GrowthN/AMetagenomi Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETUpcoming EarningsMetagenomi's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Metagenomi Earnings HeadlinesMetagenomi (NASDAQ:MGX) Price Target Cut to $5.00 by Analysts at Chardan CapitalJuly 7, 2026 | americanbankingnews.comMetagenomi Announces Board Changes and Shareholder Meeting ResultsJune 10, 2026 | tipranks.comSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.July 14 at 1:00 AM | TradeSmith (Ad)Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?June 5, 2026 | prnewswire.comMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comMetagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50May 14, 2026 | msn.comSee More Metagenomi Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email. Email Address About MetagenomiMetagenomi (NASDAQ:MGX) (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives. Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors. The company works with manufacturers to enhance biofuel production, create greener chemical intermediates and develop more effective formulations for detergents, textiles and crop protection. In the biopharmaceutical realm, Metagenomi’s novel genome-editing components have the potential to drive next-generation gene therapies and precision medicine approaches by enabling targeted modifications in living cells. Founded in 2019 and headquartered in South San Francisco, Metagenomi has rapidly expanded through strategic collaborations and research partnerships with industry leaders and academic institutions. The company’s management team combines deep expertise in genomics, computational biology and industrial biotechnology, positioning Metagenomi to serve global markets and address growing demand for sustainable, biologically derived solutions. As it advances its pipeline programs and broadens its partner network, Metagenomi continues to pursue breakthrough innovations that bridge metagenomics data with real-world manufacturing needs.View Metagenomi ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
